An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure
| Autor: | F. O. Müller, J. Terblanché, M. V. Middle, G. Groenewoud, Robert Schall, H. K. L. Hundt |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
medicine.medical_specialty Metabolic Clearance Rate medicine.medical_treatment Thiazines Urology Cmax Pharmacology Meloxicam Excretion Electrolytes Double-Blind Method Pharmacokinetics Furosemide medicine Humans Drug Interactions Pharmacology (medical) Diuretics Aged Heart Failure Cross-Over Studies business.industry Anti-Inflammatory Agents Non-Steroidal Original Articles Middle Aged Crossover study Thiazoles Area Under Curve Pharmacodynamics cardiovascular system Female Diuretic business Half-Life medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 44:393-398 |
| ISSN: | 0306-5251 |
| Popis: | Aims To evaluate the interaction of meloxicam with frusemide in patients with compensated cardiac failure. Methods Nineteen patients with Grade II or III compensated chronic cardiac failure completed this randomized, double-blind, cross-over study. The patients received 40 mg frusemide day(-1) for 7 days. Thereafter, patients received either 15 mg meloxicam plus 40 mg frusemide day(-1), or one placebo tablet plus 40 mg frusemide day(-1) for 7 days. After a washout period of 7 days during which patients received 40 mg frusemide day(-1) for 7 days, the patients were crossed over to the alternate treatment. The effect of concomitant ingestion of meloxicam and frusemide on frusemide-induced diuresis, urine and serum electrolytes, urinary frusemide excretion, and plasma frusemide pharmacokinetics was also determined. Results The estimate (90% confidence interval) of the '(frusemide + meloxicam)/(frusemide alone)' mean ratio of the variables Cmax, AUC(SS) and Cmax/AUC(SS) for plasma frusemide were 121% (101% to 145%), 106% (96.4% to 117%), and 114% (98.3% to 132%), respectively. Similarly, the estimate (90% confidence interval) of the '(frusemide + meloxicam)/(frusemide alone)' of the mean ratio of the variable cumulative urinary frusemide excretion after multiple doses of frusemide were 123% (101% to 150%) for the period 0-8 h, and 122% (105% to 142%) for the period 0-24 h after drug administration on day 7. The estimate (90% confidence interval) of the '(frusemide + meloxicam)/(frusemide alone)' mean ratio of the pharmacodynamic variables cumulative sodium excretion was 105% (95.2% to 116%) for the period 0-8 h and 108% (96.5% to 121%) for the period 0-24 h after drug administration on day 7. Conclusions Meloxicam may lead to slightly increased maximum concentrations of frusemide in plasma, as well as to slightly increased urinary excretion of frusemide, without affecting the pharmacodynamics of frusemide. Thus there is no clinically significant pharmacokinetic or pharmacodynamic interaction of meloxicam with frusemide following repeated co-administration of meloxicam and frusemide to patients with compensated chronic cardiac failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text